Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY -3,006,966.31, representing a decrease of 133.65% year-over-year[10] - Operating revenue for Q1 2023 was CNY 29,231,472.90, down 17.64% from CNY 35,493,365.06 in the same period last year[10] - Total operating revenue for Q1 2023 was CNY 29,231,472.90, a decrease of 17.5% compared to CNY 35,493,365.06 in Q1 2022[38] - Total operating costs increased to CNY 33,443,593.46 in Q1 2023, up 22.5% from CNY 27,336,812.67 in Q1 2022[39] - Net profit for Q1 2023 was a loss of CNY 3,006,966.31, compared to a net profit of CNY 8,936,436.40 in Q1 2022[40] - The company's earnings per share (EPS) for Q1 2023 was -0.05, down from 0.22 in Q1 2022[40] - The total comprehensive income amounted to -2,478,079.04 yuan, compared to 9,577,473.26 yuan in the previous year[43] - Basic and diluted earnings per share were both -0.04 yuan, down from 0.23 yuan year-over-year[43] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 433,954,356.85, a slight increase of 0.15% compared to the end of 2022[10] - The company's asset-liability ratio increased slightly to 18.16% for consolidated figures, compared to 17.34% at the end of 2022[10] - Total liabilities increased to CNY 78,784,432.27 from CNY 75,138,629.71, reflecting a rise of 3.5%[32] - Short-term borrowings rose significantly to CNY 31,000,000.00 from CNY 17,006,572.23, an increase of 82.2%[31] - Total equity decreased to CNY 355,169,924.58 from CNY 358,178,557.34, a decline of 0.6%[32] - Total liabilities increased to CNY 78,203,703.16 in 2023 from CNY 74,808,715.29 in 2022, reflecting a growth of 5.5%[36] - Total equity decreased to CNY 356,528,086.24 in 2023 from CNY 359,006,165.28 in 2022, a decline of 0.7%[36] Cash Flow - The company's cash flow from operating activities improved by 34.69%, reaching CNY -7,646,015.20 compared to CNY -11,707,731.93 in Q1 2022[10] - Cash inflows from operating activities were 37,289,256.27 yuan, an increase from 27,325,217.10 yuan in the same period last year[44] - Cash outflows from operating activities totaled 44,935,271.47 yuan, compared to 39,032,949.03 yuan in the previous year[46] - The net cash flow from operating activities was -7,646,015.20 yuan, an improvement from -11,707,731.93 yuan year-over-year[46] - Cash outflows for investing activities were 16,552,276.64 yuan, significantly higher than 4,675,328.42 yuan in the previous year[46] - Cash inflows from financing activities increased to 51,000,000.00 yuan from 40,000,000.00 yuan year-over-year[46] - The net cash flow from financing activities was 13,513,480.54 yuan, down from 19,625,773.23 yuan in the previous year[46] - The ending cash and cash equivalents balance was 34,428,100.42 yuan, a decrease from 40,192,157.50 yuan year-over-year[46] - The company reported a net decrease in cash and cash equivalents of -10,684,811.30 yuan compared to an increase of 3,242,712.88 yuan in the previous year[46] Shareholder Information - The number of ordinary shareholders as of the report date was 12,721[18] - The largest shareholder, Yan Hejing, holds 47.58% of the total shares, amounting to 26,623,000 shares[19] - The company reported a total of 38,691,082 shares held by the top ten shareholders, representing 69.14% of total shares[21] - The company has no significant changes in shareholder relationships among the top ten shareholders[21] - The company has not conducted any share buybacks during the reporting period[24] Operational Highlights - The company plans to focus on market expansion and new product development in the upcoming quarters[34] - Research and development expenses for Q1 2023 were CNY 2,464,389.29, slightly up from CNY 2,408,734.34 in Q1 2022[39] - The company reported other income of CNY 969,079.63 in Q1 2023, down from CNY 1,472,501.74 in Q1 2022[39] - The company experienced a credit impairment loss of CNY 246,158.06 in Q1 2023, compared to CNY 30.50 in Q1 2022[39] Legal and Compliance - The company has a commitment to fulfill disclosed promises without any overdue situations during the reporting period[25] - The company has not engaged in any litigation or arbitration matters during the reporting period[24] - The company has not provided any external guarantees or loans during the reporting period[24] - The company has not been subject to any investigations or penalties during the reporting period[24]
大禹生物(871970) - 2023 Q1 - 季度财报